Arcutis Biotherapeutics, Inc. (ARQT) vs MBX Biosciences, Inc. Common Stock (MBX)
A side-by-side comparison of Arcutis Biotherapeutics, Inc. and MBX Biosciences, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ARQT
Arcutis Biotherapeutics, Inc.
$24.17HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
MBX
MBX Biosciences, Inc. Common Stock
$56.07HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
Total return — ARQT vs MBX
growth of $100 · dividends reinvested · last 2yARQT +135.9% (+53.6%/yr)MBX +147.5% (+57.3%/yr)MBX compounded faster over this window
ARQT MBX
ARQT vs MBX: by the numbers
- •ARQT is the larger company ($3.02B vs $2.67B market cap).
- •ARQT is profitable (6.15% net margin) while MBX runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | ARQT | MBX |
|---|---|---|
| P/E ratio | 115.92 | N/A |
| Forward P/E | 48.62 | N/A |
| P/S ratio | 6.52 | N/A |
| P/B ratio | 13.71 | 6.52 |
| EV / EBITDA | 83.41 | N/A |
| FCF yield | 1.30% | N/A |
Profitability
| Metric | ARQT | MBX |
|---|---|---|
| Gross margin | 91.14% | 0.00% |
| Operating margin | -3.25% | 0.00% |
| Net margin | 6.15% | 0.00% |
| ROE | 12.93% | -25.47% |
| ROIC | 9.95% | -28.60% |
Growth (annualized)
| Metric | ARQT | MBX |
|---|---|---|
| Total return CAGR (5Y) | -0.28% | N/A |
Frequently asked
- Is ARQT or MBX more profitable?
- ARQT runs the higher net margin — ARQT at 6.15% versus MBX at 0.00%.
Go deeper
Dig into the metrics
Arcutis Biotherapeutics P/E ratioArcutis Biotherapeutics ROEMBX Biosciences, Inc. Common Stock ROEArcutis Biotherapeutics operating marginMBX Biosciences, Inc. Common Stock operating marginArcutis Biotherapeutics revenue growthMBX Biosciences, Inc. Common Stock revenue growthArcutis Biotherapeutics free cash flowMBX Biosciences, Inc. Common Stock free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.